Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMiguel Sanmamed, MD, PhD
Assistant Professor AdjunctAbout
Research
Publications
2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Lopez-Janeiro A, González-Gomariz J, Issa F, Hester J, Porciuncula A, Teijeira A, Luri-Rey C, Ruiz-Guillamon D, Perez-Gracia J, Perez-Ruiz E, Barragan I, Martín-Algarra S, Sanmamed M, Ortego I, Rodriguez-Ruiz M, Alexandru R, Rodriguez I, Arrieta-Aranzueque S, Rimm D, Aung T, Schalper K, de Andrea C, Melero I. Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer. Journal Of Clinical Investigation 2026, 136: e200987. PMID: 42065248, PMCID: PMC13132367, DOI: 10.1172/jci200987.Peer-Reviewed Original ResearchRadiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
Marco S, Fernández M, Honorato B, Juanarena N, Sainz C, Andueza A, Gould D, Anderson S, de Andrea C, Domínguez P, Wong P, Vásquez C, Narinda I, Unzu C, Isola S, Tavira B, Ariz M, Camps G, Sanmamed M, Pardo J, Labiano S, Alonso M, Marco-Sanz J, Guruceaga E, Collantes M, Simón J, Peñuelas I, Fernández-Irigoyen J, Santamaría E, Prieto J, Dubrot J. Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. Cancer Cell 2026, 44: 995-1011.e12. PMID: 41875889, DOI: 10.1016/j.ccell.2026.02.013.Peer-Reviewed Original ResearchAn ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression
Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Wermke M. An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression. Endocrine Abstracts 2026 DOI: 10.1530/endoabs.116.c1.Peer-Reviewed Original ResearchReply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Arriola E, Wolf J, Villaruz L, Bertulis J, Studeny M, Bouzaggou M, Fang X, Morgensztern D. Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond. Journal Of Clinical Oncology 2026, 44: 1062-1064. PMID: 41570262, DOI: 10.1200/jco-25-02654.Commentaries, Editorials and LettersSafety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.
Sanmamed M, de Andrea C, Ruiz-Guillamón D, Rodriguez-Ruiz M, Ortego I, Eguren-Santamaría I, Benito A, López-Janeiro A, Gonzalez Gomariz J, Villalba-Esparza M, Molina A, Krasko A, Ponz-Sarvise M, Lopez-Picazo J, Gomis G, Molero-Glez P, Alexandru R, Pérez-Domínguez P, Rodriguez I, Sánchez-Gregorio S, Perez-Gracia J, Melero I. Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab. Clinical Cancer Research 2026, 32: 1036-1045. PMID: 41543348, DOI: 10.1158/1078-0432.ccr-25-2502.Peer-Reviewed Original ResearchOrthotopic pleural mesothelioma mouse model
García R, Moreno D, Camps G, Vera L, Sanmamed M, Berraondo P, Aranda F. Orthotopic pleural mesothelioma mouse model. Methods In Cell Biology 2026 DOI: 10.1016/bs.mcb.2026.06.002.Books
2025
Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic
Eguren-Santamaria I, Melero I, Rodríguez I, Ortego I, Armero M, Galvez-Cancino F, López-Janeiro A, De Andrea C, Sanmamed M. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic. Journal For ImmunoTherapy Of Cancer 2025, 13: e011279. PMID: 41161818, PMCID: PMC12574409, DOI: 10.1136/jitc-2024-011279.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsBrief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
Di Frisco M, Sanmamed M, Ferrández J, Vilalta A, Sogbe M, García-Goñi M, Martin-Palmero Á, Aso-González S, Nadal E, Signes-Costa J, Gambardella V, Seguí Manzaneque V, Martin P, Insa A, Franco J, Lores C, de Torres J. Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors. Journal Of Thoracic Oncology 2025, 21: 328-333. PMID: 41130410, DOI: 10.1016/j.jtho.2025.10.007.Peer-Reviewed Original ResearchAssociation of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients
de Andrea C, Abengozar-Muela M, Arranz J, Climent M, Puente J, Vizcay Á, de la Fuente L, Jurado J, Bonfill T, Santander C, Villa J, Pujol E, Rosero A, Gomez J, Fernández E, Fernández C, Ramirez I, Arnáiz P, López-Janeiro Á, Melero I, Sanmamed M, Pérez-Gracia J. Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients. OncoImmunology 2025, 14: 2538687. PMID: 40778981, PMCID: PMC12952735, DOI: 10.1080/2162402x.2025.2538687.Peer-Reviewed Original ResearchDasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy.
Redin E, Otegui N, Santos M, Leon S, Redrado M, Serrano D, Fernandez de Pierola E, Russo-Cabrera J, Ferrer I, Olmedo M, Diaz-Lagares A, Houry M, Vicent S, Vilalta A, Mondelo-Macía P, García-González J, León-Mateos L, Gonzalez A, Paz-Ares L, López R, Sanmamed M, Montuenga L, Calvo A. Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy. Cancer Research 2025, 85: 3910-3929. PMID: 40712061, DOI: 10.1158/0008-5472.can-24-2772.Peer-Reviewed Original Research